Cobra and Manchester Uni receive grant for biologics scale-up

By Fiona BARRY contact

- Last updated on GMT

Scale-up needs 'greater predictability and certainty', says industry
Scale-up needs 'greater predictability and certainty', says industry

Related tags: Manufacturing

Cobra Biologics, a Swedish contract development and manufacturing organisation, has launched a project to improve scale-up of biologics with the University of Manchester, UK.

The two-year collaboration will focus on mammalian cell bioprocessing used to make biologic pharmaceuticals.

The main aim is to develop a profile of cell process characteristics and attributes associated with cell line development and subsequent scale-up for production that will allow the development of early stage predictors of success for clone selection and manufacturability,​” Cobra CEO Peter Coleman told this publication.

The company said the pharmaceutical industry needs “greater predictability and certainty in process development and scale-up​” for immuno-oncology biologics.

FLIP grant

The research will be supported via the FLexible Interchange Programme (FLIP) Scheme awarded by the Biotechnology and Biological Sciences Research Council (BBSRC).

The awards allows academic scientists to be seconded to roles in industry for investigative projects which will benefit both partners.

The grant will pay the University of Manchester to cover the salary of biotechnology professor Alan Dickson while he spends 40% of his working time with Cobra. It will also fund a full-time research technician for one year at the UK’s University of Manchester, who will also contribute to the research.  

Cobra said it will also provide support “by directly aligning a number of internal R&D programmes to the grant remit and committing up to 20% of its internal R&D budget to the programme.​” 

UK and Sweden

The agreement will give Cobra access to Manchester’s academic research group, while Prof Dickson will receive Cobra’s production data and learn about industrial manufacturing processes.

Professor Dickson has links and collaborations with UK and international academics, addressing all aspects of production of biopharmaceuticals,​” said Cobra’s chief scientific officer, Daniel Smith.

The insights of Professor Dickson into the various processes and tools used, combined with historical data case studies undertaken by Cobra Biologics, will allow better definition and enhancement of our current manufacturing processes and to build towards the idealised platforms and processes for future manufacture of innovator and biosimilar molecules.​”

The R&D will take place at the University of Manchester and at Cobra’s sites in Staffordshire, UK and Sodertalje, Sweden.

The organisations did not disclose financial and intellectual property terms of the deal.

Related news

Related products

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more